Company* |
University/ |
Type Of |
Product Area | Details (Date) |
| | ||||
ACE |
U.S. Naval Medical Research Center |
Collaboration |
Deal to progress ACE's ACE393 through Phase II trials |
The vaccine is being developed for treating travelers' diarrhea caused by Campylobacter infection; terms of the deal were not disclosed(9/7) |
Acologix Inc.* |
University of Maryland at Baltimore |
License agreement |
Acologix licensed technology for potential treatment of interstitial cystitis |
Licensed patents relate to hep- arin-binding epidermal growth factor-like growth factor and therapies targeting anti-proliferative factor (9/6) |
Adenosine |
National Institutes of Health |
License agreement |
Adenosine got rights to adenosine antagonists for treating cancer |
The antagonists also will be studied for improving the efficacy of vaccines; terms of the deal were not disclosed (9/12) |
Adenosine |
University of Massachusetts Medical School |
License agreement |
Adenosine got rights to technology for use in cardiac applications |
The licensed patent is titled, "Adenosine as a positive inotrope in the compromised heart"; terms of the deal were not disclosed (9/12) |
Advanced Cell |
WiCell Research Institute |
Collaboration |
To jointly distribute to U.S. scientists a range of new cell lines |
The deal is contigent on the U.S. federal government's recognition and funding of the cell lines (9/12) |
Affymetrix |
Peter MacCallum |
Collaboration |
Five-year deal focused on translational research projects |
Researchers will use Affymetrix GeneChip microarray technology to analyze genomic information; the initial focus is ovarian cancer and carcinomas of unknown origin (9/27) |
Affymetrix |
Partners HealthCare |
Collaboration |
Deal to develop micro- array-based diagnostics for complex diseases |
The three-year translational research collaboration targets diseases such as newborn hearing loss, autism and hypertrophic cardiomyopathy (9/7) |
Alkermes |
Rensselaer Polytechnic Institute |
License agreement |
Alkermes got exclusive rights to a family of novel opioid receptor compounds |
Rensselaer gets an up-front payment and is eligible to receive milestone and royalty payments; the program targets various central nervous system disorders (10/5) |
BioLineRx |
Ben-Gurion University of the Negev and Clalit Health Services (both of Israel) |
License agreement |
BioLineRx got rights to BL-3030, an antisense drug for treating inflammatory diseases |
Terms of the exclusive, worldwide license agreement were not disclosed (9/8) |
CardioVascular |
Orthopaedic Education and Research Institute of Southern California |
Collaboration |
Deal to conduct a feasibility study in patients with chronic back pain caused by degenerative disc disease |
The goal is to determine if back pain is related to poor blood flow and decreased nutrition of the discs in the lower back (9/13) |
Celldex |
Ludwig Institute for Cancer Research |
Collaboration |
Multityear deal focused on a series of tumor- associated antigens (TAAs) |
They plan to develop immuno-therapies using Celldex's APC targeting monoclonal antibodies and LICR's TAAs; LICR has rights to use resulting products in clinical trials (10/23) |
Cobra Bio- |
U.S. Naval |
CRADA |
Cobra will construct and test a vaccine against malaria |
Cobra will use its ORT-VAC oral vaccine delivery technology in the effort; terms of the deal were not disclosed (10/16) |
Cumbre |
The Global Alliance for TB Drug Development |
Collaboration |
Deal to jointly pursue development of new drugs against tuberculosis |
The focus is on two classes of multifunctional antibodies; the TB Alliance will have rights to resulting products in TB and certain other diseases; Cumbre will have rights in other infectious diseases (9/27) |
Dyax Corp. |
Commonwealth Scientific and Industrial Research Organisation (Australia) |
Collaboration |
Deal to discover and develop therapeutic antibodies for treating cancer |
Dyax will screen clinical candi- dates, and CSIRO will provide reagents and in vitro assays, as well as certain preclinical development work; Dyax will have the option to advance resulting anti- body leads into the clinic (11/29) |
Edison |
Institute of Vision, University of Sao Paulo (Brazil) |
Collaboration |
Deal to develop drugs targeting Leber's hereditary optic neuropathy, which leads to blindness |
The institute and its research consortium will evaluate Edison drugs that target inherited mitochondrial diseases; terms were not disclosed (10/2) |
Evogenix Ltd. |
National Institutes of Health |
CRADA |
Deal to develop anti- antibody therapies against PAMP, an angiogenesis cancer target |
EvoGenix will provide antibodies against PAMP; National Cancer Institute researchers will test the antibodies; further details were not disclosed (11/2) |
Galapagos NV |
Cystic Fibrosis Foundation Therapeutics Inc. |
Collaboration extension |
They extended for 15 months a target discovery deal in cystic fibrosis |
Galapagos unit BioFocus DPI gets research fees of €0.8M; their alliance began in April 2005 (11/22) |
Galapagos NV |
Institute for OneWorld Health |
Collaboration |
Deal focused on development of drugs for treating diarrheal diseases |
Galapagos unit BioFocus DPI will work to identify drug candidates for the program; it is entitled to more than €3M over the 2.5-year contract (9/6) |
Genzyme Corp. |
Medicines for Malaria Venture (Switzerland) and the Broad Institute |
Collaboration |
They expanded collaboration to discover and develop therapeutics for treating malaria |
There are four early discovery projects in their portfolio; MMV will get access to resulting products on a royalty-free basis (10/18) |
Hana |
Albert Einstein College of Medicine |
License agreement |
Hana got rights to Menadione, a preclinical product for skin rash associated with use of epidermal growth factor receptor inhibitors |
The rights are exclusive and worldwide, and include sublicensing rights; the college would get royalties on resulting sales (10/16) |
Humanyx |
Genome Institute of Singapore |
Collaboration |
Deal to develop antibody therapies against the H5N1 virus |
GIS gets rights to use Humanyx's phage library in the effort; terms of the deal were not disclosed (11/28) |
Interleukin |
Yonsei University (South Korea) |
Collaboration |
Deal to study the role of genetics in spine fractures |
The focus is exploring potential links between interleukin-1 gene variations and spine fractures in postmenopausal Korean women (9/7) |
Introgen |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Introgen got rights to nanoparticle-based delivery technology |
The cancer-directed technology is based on delivery of large molecules using nanoparticle delivery complexes; terms of the deal were not disclosed (11/16) |
Introgen |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Introgen got rights to patent applications covering combinationcancer therapies |
The patents are directed at the use of Introgen's Advexin with epidermal growth factor receptor inhibitors; Introgen sponsors research at the center; license terms were not disclosed (11/3) |
InViragen LLC* |
Centers for Disease Control and Prevention |
License agreement |
InViragen got rights to vaccine technology applicable to multiple viral diseases |
Targets include dengue fever and West Nile disease; terms of the exclusive license were not disclosed (9/15) |
Lentigen |
University of Pennsylvania |
Agreement |
To develop the company's lentiviral vector for clinical gene therapy research |
Terms of the deal were not disclosed; the focus is immuno-therapy approaches in cancer indications (9/7) |
Lexicon |
U.S. Army Medical Research & Materiel Command |
Research program |
Deal to develop drugs for spinal muscular atrophy was extended an additional year |
Lexicon will get $2.5M in funding for the one- year extended term; it has a deal with the SMA Foundation for development of resulting drug candidates (10/11) |
Lux |
National Institutes of Health |
License agreement |
Lux got rights to LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye |
Pivotal trials for prevention of rejection in corneal transplantation were expected to begin in early 2007; terms of the worldwide deal were not disclosed (11/7) |
Lux |
Rutgers University |
License agreement |
Lux gained access to Rutger's polyarylate patent estate |
Lux plans to use the technology in the treatment of eye diseases; terms of the deal were not disclosed (9/13) |
MethylGene Inc. |
CHDI Inc. |
Agreement |
CHDI is supporting the companies' program to develop histone deacetylase inhibitors for Huntington's disease |
CHDI is providing up to $1.5M in initial funding, and providing research support; MethylGene and EnVivo retain commercial rights (11/16) |
MorphoSys |
Burnham Institute for Medical Research |
Agreement |
The institute will use antibody technology from MorphoSys to identify and validate target molecules |
MorphoSys retains commercialization rights for all emerging antibodies, in research and in therapeutic or diagnostic applications; terms of the deal were not disclosed (11/28) |
Nastech |
City of Hope |
License agreement |
Nastech got rights to Dicer- substrate RNA interference technology |
Nastech's rights are exclusive for five targets; broader rights are nonexclusive; terms of the deal were not disclosed (11/8) |
Novavax Inc. |
Centers for Disease Control and Prevention |
CRADA |
The CDC will evaluate the company's H5N1 pandemic influenza vaccine candidate |
Research will include preclinical testing against live bird flu virus (10/31) |
Omrix Bio- |
National Institute of Allergy and Infectious Diseases |
CRADA |
Deal to to develop new antibody- based therapeutics for treating avian influenza |
They will use the NIAID's expertise in influenza and vaccines and Omrix's capabilities in man- ufacturing and antibody development; terms of the deal were not disclosed (10/9) |
Open |
National Cancer Institute |
Agreement |
The NCI will evaluate the effectiveness of certain OBI technology |
The NCI will test lentiviral microRNA-adapted short hairpin RNA technology in 135 specifically targeted cancer genes (10/30) |
Orion |
Mayo Clinic |
Collaboration |
Deal to study the clinical utility of Orion's breast cancer screening tests |
The technology is based on epigenetic biomarkers; they also will use it in more than a dozen other cancer types (11/19) |
Oxford |
The Foundation Fighting Blindness |
Collaboration |
Deal to develop gene therapy products for treating eye diseases; it follows a 2003 deal for preclinical development of RetinoStat |
The first product in the expanded deal is StarGen for treating Stargardt disease; FFB and investors will make an up-front payment to Oxford, and purchase up to $3.9M in stock; they would get a royalty on any resulting sales (10/2) |
Pain |
Albert Einstein College of Medicine |
License agreement |
Nastech got rights to a radiolabeled monoclonal antibody technology |
The college gets an up-front fee and may get up to $3.5M in milestone payments, as well as a 4% sales royalty; rights are exclusive in oncology and infectious disease indications (11/8) |
Phase |
Duke University |
License agreement |
PhaseBio got certain rights to technology associated with drug delivery based on ELP technology |
PhaseBio has worldwide rights to use the technology with its drugs, and in third-party arrangements; terms of the deal were not disclosed (11/8) |
Raptor |
Washington University |
License agreement |
Raptor got rights to use Mesd reagents in the treatment of cancer and osteoporosis |
Mesd is a chaperone protein that may be useful in the regulation of the LRP5 and LRP6 receptors; terms of the worldwide deal were not disclosed (11/6) |
Senetek plc |
Institute of Bioorganic Chemistry of the Polish Academy of Sciences |
License agreements |
Senetek got rights to an anticancer agent and to three com- pounds for treatment of skin aging |
The first technology targets brain cancer through RNA interference; the institute is entitled to royalties on resulting sales (11/7) |
Somanta |
University of Bradford (UK) |
Collaboration |
Somanta got rights to discoveries in certain areas of cancer research at the university |
As part of the deal, the university's Institute for Cancer Therapeutics will continue development work on two Somanta pre-clinical cancer drugs (9/19) |
Stem Cell |
Massachusetts Eye and Ear Infirmary |
Collaboration |
MEEI will evaluate SCI's PluriCells technology in the formation of human tissues implicated in hearing loss |
MEEI gets access to the pluri- potent stem cell technology; SCI will get nonexclusive rights to resulting intellectual property (10/10) |
Stem Cell |
University of Twente (the Netherlands) |
Collaboration |
Deal to explore the bone-forming properties of SCI's PluriCells technology |
The university gets access to the pluripotent stem cell technology; SCI will get nonexclusive rights to resulting intellectual property (10/3) |
Synairgen plc(UK; LSE:SNG) |
University of Southampton (UK) |
License agreement |
Synairgen got exclusive rights to peptide technology directed against asthma |
The peptide is believed to suppress the effects of both interleukin-4 and IL-13; terms of the deal were not disclosed (11/15) |
Transition |
Juvenile Diabetes Research Foundation |
Partnership |
The JDRF will support development of Transition's diabetes regenerative product, GLP1-I.N.T. |
Transition is eligible to receive milestone-driven payments of up to $4M over two years; further terms were not disclosed (9/13) |
Trophos SA* |
CHDI Inc. |
Collaboration extension |
They extended deal to discover and develop drugs for Huntington's disease |
They will build on earlier work on compounds that confer a survival benefit on primary striatal neurons; Trophos retains rights to resulting candidates (9/21) |
U.S Genomics |
Lahey Clinic |
Agreement |
Deal to study the rolemicroRNAs play in the development of urological cancers |
The objective is to develop more accurate prognoses for bladder and prostate cancers (10/17) |
Vical Inc. |
Six research institutions |
License agreement |
The institutions got rights to DNA delivery technology, for use in product development |
Licenses were granted to Fred Hutchinson Cancer Research Center, Texas Tech University Health Sciences Center, University of Iowa, University of Notre Dame, University of Pittsburgh and University of Washington (9/19) |
Viropro Inc. |
National Research Council-Biotechnology Research Institute |
License agreement |
Viropro got rights to use the NRC's inducible expression systems |
The technology will be used in the production of recombinant human interferon beta; terms were not disclosed; licenses covering other proteins were being negotiated (10/26) |
| | ||||
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
CRADA = Cooperative Research and Development Agreement. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; | ||||
LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
